Mene Pangalos (AstraZeneca via YouTube)

As­traZeneca vaults to the front of the Covid-19 vac­cine race, team­ing up to glob­al­ize Ox­ford can­di­date

Be­fore last week, As­traZeneca was watch­ing with the rest of the world as re­searchers at Ox­ford Uni­ver­si­ty’s Jen­ner In­sti­tute be­gan push­ing their Covid-19 vac­cine in de­vel­op­ment in­to the pub­lic eye. And then Mene Pan­ga­los, the EVP of bio­phar­ma R&D, talked to John Bell, an Ox­ford pro­fes­sor and long­time friend.

With­in days, they sketched the out­lines of a col­lab­o­ra­tion un­veiled to­day that gives As­traZeneca a cen­tral role in the glob­al de­vel­op­ment, man­u­fac­tur­ing and dis­tri­b­u­tion of the vac­cine — should the Phase I/II re­sults come back pos­i­tive in the sum­mer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.